GBA1 and Parkinson disease: We have therefore sought to compare the therapeutic effects of the previously established neuronal specific vector versus two novel AAV9 constructs, where the expression of the human GBA1 gene is driven by the ubiquitous chicken β-actin promoter in the CBA and CAG sequences, with the CAG promoter having recently been utilized in the successful translation of onasemnogene abeparvovec and is currently utilised in phase 1/2 trials for type 1, type 2 and PD-GBA patients (clinicaltrials.gov: NCT05487599, NCT04411654, NCT04411654).